Total
0
Shares
Recce Pharmaceuticals (RCE) - ‎Chief Scientific Officer and Executive Director Michele Dilizia - The Market Herald
‎Chief Scientific Officer and Executive Director Michele Dilizia
Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • An independent study into Recce Pharmaceutical's (RCE) R327 synthetic antiinfective has found it to be "unlike that of any antibiotic seen before"
  • The three studies sought to clarify R327's mechanism of action, with the findings set to be presented at the World Microbe Forum this June
  • They found Recce's drug rapidly and irreversibly prevented bacteria growth against a 'superbug', ultimately outperforming best in class commercial antibiotics
  • Recce Executive Director and Chief Scientific Officer Michele Dilizia says the data from this study further supports the potential of RECCE 327 to provide a novel and universal way to treat harmful infections
  • Recce Pharmaceuticals closed today's session down 0.44 per cent to trade at $1.14

An independent study into Recce Pharmaceutical's (RCE) R327 synthetic antiinfective has found it to be "unlike that of any antibiotic seen before".

The three studies sought to clarify R327's mechanism of action which are set to be presented at the World Microbe Forum in June this year.

These studies found the Recce's drug rapidly and irreversibly prevented bacteria growth against the superbug Gram-negative E. coli bacteria in both active and stationary cells, ultimately outperforming best in class commercial antibiotics.

The bactericidal effect was said to be evident immediately in all tested concentrations, with R327 "crashing" the ATP viability — a marker of live cells —of bacterial cells in minutes, reportedly faster than any antibiotic tested previously.

In key takeaways from the study, Recce also highlighted R327's ability to "rapidly and irreversibly" shut down cellular energetics and disrupt cellular bioenergetics.

Additionally, the studies found R327 does not permeabilise the cell membrane or alter the integrity of the outer membrane of E.coli cells.

For context, RCE explained current antibiotics rarely retain bactericidal activities against nondividing bacterial cells. By contrast, R327 shows significant activity against slow-growing bacteria and actively dividing cells, enabling continuous treatment of infections throughout the bacterial cell life cycle.

Recce Executive Director and Chief Scientific Officer Michele Dilizia spoke highly of the results.

"The data from this study further supports the potential of RECCE 327 to provide a novel and universal way to treat harmful infections," she said.

"We are excited about these highly encouraging results as they provide important insights regarding how RECCE 327 is able to work repeatedly against the same strain of bacteria and their superbug forms." .

Recce Pharmaceuticals closed today's session down 0.44 per cent to trade at $1.14.

RCE by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) brings ColoSTAT trial to Queensland

" Proteomics International Laboratories (ASX:PIQ) to collaborate for world’s first endometriosis test

Proteomics International Laboratories (PIQ) has penned a research agreement to develop a non-invasive test for endometriosis.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) secures two deals to integrate its diagnostic test

ResApp Health (RAP) has secured two new agreements for its smartphone-based acute respiratory diagnostic test.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" FDA requests further clarification from Paradigm Biopharmaceuticals (ASX:PAR)

The US Food and Drug Administration has requested further clarification from Paradigm Biopharmaceuticals (PAR) for its Investigational New Drug (IND) application.
Patrys (ASX:PAB) - CEO and Managing Director, Dr James Campbell - The Market Herald

" Patrys’ (ASX:PAB) clinical trials pushed back

Patrys’ (PAB) planned PAT-DX1 clinical trial will be postponed for up to six months due to global manufacturing and supply chain delays.